InMed Pharmaceuticals Inc. (INM) stock: key figures, P/E, revenue and dividend
Health Care · Canada · ISIN CA4576377002
InMed Pharmaceuticals Inc. financials
| Fiscal year | 2025 | 2026 |
|---|---|---|
| Revenue | 4.94 m USD | – |
| Gross profit | 2.33 m USD | – |
| EBIT | -11.33 m USD | -12.81 m USD |
| Net income | -8.16 m USD | -12.56 m USD |
| Diluted EPS – continuing operations | -11.39 USD | -3.12 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc. operates as a pharmaceutical drug development company in the United States. The company researches and develops cannabinoid-based pharmaceuticals products. Its product candidates include INM-901 for Alzheimer's disease, INM-089 for dry age-related macular degeneration, and INM-755, a cannabinol cream. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.
More stocks
- EWSB Bancorp, Inc. /MD/ (EWSB)
- TX Rail Products, Inc. (TXRP)
- SafeSpace Global Corp (SSGC)
- Syra Health Corp (SYRA)
- Atlantis Glory Inc. (AGLY)
- CJ Seafood Corp. Pfd. Series 1 (011155.KS)
- Rise Gold Corp. (RYES)
- HeartSciences Inc. (HSCS)
- JEWETT CAMERON TRADING CO LTD (JCTC)
- AtlasClear Holdings, Inc. (ATCH)
- INTENSITY THERAPEUTICS, INC. (INTS)
- Sintx Technologies, Inc. (SINT)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.